Evidence map›Paper›PMID 40508201›Full record

ArticleInternational journal of molecular sciences2025

SARS-CoV-2-Derived RNA Fragment Induces Myocardial Dysfunction via siRNA-like Suppression of Mitochondrial ATP Synthase.

Shota Nukaga, Rina Fujiwara-Tani, Takuya Mori, Isao Kawahara, Ryoichi Nishida, Yoshihiro Miyagawa, Kei Goto, Hitoshi Ohmori, Kiyomu Fujii, Takamitsu Sasaki and 6 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shota NukagaDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Rina Fujiwara-TaniDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Takuya MoriDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Isao KawaharaDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Ryoichi NishidaDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.ORCID 0009-0008-6517-8420
Yoshihiro MiyagawaDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Kei GotoDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Hitoshi OhmoriDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Kiyomu FujiiDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Takamitsu SasakiDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Chie NakashimaDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Yi LuoDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Shiori MoriDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Shingo KishiDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Ruiko OgataDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Hiroki KuniyasuDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.ORCID 0000-0003-2298-8825

Funding

Ministry of Education, Culture, Sports, Science and Technology 24K14281Ministry of Education, Culture, Sports, Science and Technology 24K20535Ministry of Education, Culture, Sports, Science and Technology 25K14462Ministry of Education, Culture, Sports, Science and Technology 25K14487
6 · The paper itself

Abstract

Myocardial injury is a critical determinant of prognosis in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; however, its underlying mechanisms remain incompletely understood. In this study, we examined the effects of SARS-CoV-2-derived RNA fragments on human cardiomyocytes. We identified a 19-nucleotide sequence within the viral genome that shares complete sequence homology with the human F1F0 ATP synthase subunit alpha gene (ATP5A). This sequence was found to associate with Argonaute 2 (AGO2) and downregulate ATP5A expression via a mechanism analogous to RNA interference. Consequently, oxidative phosphorylation was suppressed in cardiomyocytes, leading to impaired myocardial maturation and the emergence of heart failure-like phenotypes. Notably, exosome-mimetic liposomal delivery of this RNA fragment to cardiomyocytes reproduced the ATP5A-suppressive effect. These findings suggest that SARS-CoV-2-derived RNA fragments may contribute to myocardial injury through the siRNA-like modulation of mitochondrial gene expression. Further validation in animal models and patient-derived materials is warranted.

Indexed as

COVID-19Mitochondrial Proton-Translocating ATPasesRNA, Small InterferingRNA, ViralSARS-CoV-2AnimalsArgonaute ProteinsHumansMyocytes, CardiacOxidative PhosphorylationAGO2 protein, humanArgonaute ProteinsMitochondrial Proton-Translocating ATPasesRNA, Small InterferingRNA, ViralATP5F1F0 ATP synthaseheart injurySARS-CoV-2siRNA

Identifiers

PMID40508201
PMCPMC12156209

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.